Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
News
Sports
TV & Film
About Us
Contact Us
Copyright
© 2024 PodJoint
Podjoint Logo
US
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/2e/7c/19/2e7c1961-be3c-525a-c62e-64de8c49402f/mza_17042035172370226209.jpg/600x600bb.jpg
BioVenture VoiCes with Chris Garabedian
BiotechTV
27 episodes
1 day ago
Hosted by Chris Garabedian, meet the leading Voices in the BioVenture community and hear their insights and perspectives on the challenges and successes with VC investing.
Show more...
Life Sciences
Science
RSS
All content for BioVenture VoiCes with Chris Garabedian is the property of BiotechTV and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Hosted by Chris Garabedian, meet the leading Voices in the BioVenture community and hear their insights and perspectives on the challenges and successes with VC investing.
Show more...
Life Sciences
Science
https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/43070706/43070706-1751282651694-e2eb9a961960c.jpg
Episode 22: Adjuvant Capital's Glenn Rockman
BioVenture VoiCes with Chris Garabedian
1 hour 12 minutes 41 seconds
4 months ago
Episode 22: Adjuvant Capital's Glenn Rockman

Glenn Rockman describes the introduction to impact investing he gained from working for J.P. Morgan and along with the Gates Foundation on the Global Health Investment Fund, and how the idea of investing for public good ultimately sparked Adjuvant Capital in 2019. Armed with a $300M+ fund that was raised from numerous foundations and for-profit funds in 2021, Adjuvant has been investing in public health technologies, post proof of concept, to help accelerate their development and ultimately make them more accessible to those around the world who need them.

BioVenture VoiCes with Chris Garabedian
Hosted by Chris Garabedian, meet the leading Voices in the BioVenture community and hear their insights and perspectives on the challenges and successes with VC investing.